Alkem Laboratories Limited (BOM:539523)

Market Cap	657.37B +11.1%
Revenue (ttm)	147.12B +13.5%
Net Income	23.02B +6.3%
EPS	192.51 +6.3%
Shares Out	n/a
PE Ratio	28.56
Forward PE	27.84
Dividend	53.00 (0.97%)
Ex-Dividend Date	Aug 7, 2026

Volume	30,697
Open	5,578.00
Previous Close	5,452.25
Day's Range	5,475.70 - 5,793.50
52-Week Range	4,716.75 - 5,933.00
Beta	n/a
Analysts	Hold
Price Target	5,954.95 (+8.32%)
Earnings Date	May 28, 2026

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, r...

• Industry: Pharmaceutical Preparations
• Founded: 1973
• Employees: 18,785
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 539523

Financial Performance

In fiscal year 2026, Alkem Laboratories's revenue was 147.12 billion, an increase of 13.48% compared to the previous year's 129.65 billion. Earnings were 23.02 billion, an increase of 6.30%.